Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 2/20 | 0.30 |
| ▸ | PYGB | P11216 | 1/20 | 0.30 |
| ▸ | PYGM | P11217 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3289573 | 1.00 | PYGL (0.30) | PYGLPYGBPYGM | |
| SCHEMBL18992050 | 0.78 | MEN1 (0.30) | PYGLPYGBPYGM | |
| SCHEMBL18992053 | 0.78 | MEN1 (0.30) | PYGLPYGBPYGM | |
| SCHEMBL12392882 | 0.75 | — | — | |
| SCHEMBL29696488 | 0.72 | — | — | |
| SCHEMBL19307809 | 0.71 | PYGB (0.37) | PYGLPYGBPYGM | |
| SCHEMBL14975762 | 0.69 | PYGB (0.31) | PYGB | |
| SCHEMBL7942776 | 0.69 | PYGB (0.31) | PYGB | |
| SCHEMBL4282834 | 0.69 | PYGB (0.31) | PYGB | |
| SCHEMBL14975496 | 0.69 | PYGB (0.31) | PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1863813-B | Novel tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA INC | 2011-03-30 | — | — | CN | disclosed |
| US-20100311684-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-12-09 | — | — | US | disclosed |
| EP-1660511-B1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2010-11-03 | — | — | EP | disclosed |
| US-7713941-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-05-11 | — | — | US | disclosed |
| US-20080200423-A1 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2008-08-21 | — | — | US | disclosed |
| US-7268119-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-09-11 | — | — | US | disclosed |
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA, INC. (US) | 2007-06-14 | — | — | US | disclosed |
| CN-1863813-A | Novel tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA INC (AU) | 2006-11-15 | — | — | CN | disclosed |
| EP-1660511-A2 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | Biota, Inc. (AU) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021568-A2 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA, INC. (AU) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, NME1, NME2 | PYGL 1267/4885PYGB 3434/4885PYGM 2360/4885 |
| US-20080200423-A1 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents | NME1, NME2, NTPCR | PYGL 1041/4885PYGB 2979/4885PYGM 1589/4885 |
| US-20100311684-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, NME1, NME2 | PYGL 1267/4885PYGB 3434/4885PYGM 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.